🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "major milestone" in the effort against increasingly resistant strains of the infection, according to scientists.

A Worldwide Health Concern

The sexually transmitted infection are escalating around the world, with figures suggesting more than 82 million infections annually. Especially elevated rates are reported in the African continent and nations within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have reached a record high, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune step in the face of growing infection rates, increasing antimicrobial resistance and the highly restricted treatment choices currently available.”

Health officials are increasingly worried about the increase in drug-resistant strains. The global health body has designated it as a "high-priority threat". Recent surveillance showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Gain Approval

One new antibiotic, also known as a brand name, was cleared by the American regulatory agency in recent days for combating gonorrhoea. This infection can lead to major issues, including infertility. Scientists anticipate that specific application of this new drug will help hinder the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GSK, gained clearance in close succession. This medication, which is also used to treat UTIs, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin was the result of a innovative non-profit model for drug creation. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to see it through.

“This milestone signifies a huge turning point in the therapy of superbug gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Research Study Outcomes and Worldwide Availability

According to results published in a major medical journal, the new drug eradicated more than 90% of genital gonorrhoea infections. This puts it on an equal footing with the current standard treatment, which involves a dual-drug approach. The trial enrolled hundreds of patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, GARDP has the ability to register and commercialise the drug in many low-income and middle-income countries.

Doctors directly involved have expressed optimism. The availability of a easy-to-administer therapy like this is seen as a "revolutionary step" for public health efforts. This is considered vital to lessen the impact of the infection for people and to prevent the spread of extremely resistant gonorrhoea globally.